NIMH Toxicological Evaluation of Novel Ligands Program

NIMH新型配体毒理学评估项目的目的是加速人类成像新型配体的发现、开发和应用。该计划还将促进发现和开发用于临床研究的新型精神活性药物，并作为治疗精神障碍的潜在治疗药物。该项目将为NIMH现有的精神活性药物筛选项目提供重要资源，用于中枢神经系统中受体、通道和转运体结合试验中新化合物的药理学表征，以及用于评估功能活性的生化试验。新型配体毒理学评估项目也将补充加速开发用于人类研究的新型PET和SPECT脑成像配体的倡议。将协调这些活动的努力，为精神障碍临床研究的新型配体的快速和具有成本效益的开发建立一个管道。

The purpose of the NIMH Toxicological Evaluation of Novel Ligands Program is to accelerate the discovery, development, and application of novel ligands for imaging in humans. The program will also facilitate the discovery and development of novel psychoactive agents for clinical research and as potential therapeutic agents for the treatment of mental disorders. This initiative will provide a critical resource that complements NIMH’s existing Psychoactive Drug Screening Program for pharmacological characterization of novel compounds in binding assays for receptors, channels, and transporters in the central nervous system and in biochemical assays to assess functional activity. The Toxicological Evaluation of Novel Ligands Program will also complement the initiative to accelerate the Development of Novel PET and SPECT Ligands for Brain Imaging for use in human studies. Efforts of these activities will be coordinated to establish a pipeline for the rapid and cost-effective development of novel ligands for clinical studies of mental disorders.